AUS
NZ
UK
CA
USA
FRA
GER
ESP
ITA
NLD
PRT
SWE
GRC
IND
POL
BRA
ZAF
RUS
CHN
UAE
Highlights
- Mayne Pharma withdraws presentation following FDA concerns
- Company clarifies stance on product claims amid regulatory scrutiny
- Shares react sharply, entering trading pause on ASX
Mayne Pharma Group (ASX:MYX), a pharmaceutical company listed on the Australian Securities Exchange and part of the ASX300 index, is under regulatory scrutiny from the US Food and Drug Administration (FDA) following allegations of misleading promotional content related to its contraceptive product, Nextstellis.
The FDA issued a letter accusing the company of making "false or misleading claims" during a speaker presentation about the risks associated with Nextstellis, a next-generation oral contraceptive. The regulator has requested a formal response within 15 business days and noted that the claims may have resulted in the product being “misbranded” under US law.
In response, Mayne Pharma promptly withdrew the presentation in question. “Out of an abundance of caution, and as an initial and immediate action, Mayne Pharma voluntarily withdrew the speaker presentation,” the company stated in a release to the market. The company emphasized that it takes the FDA’s views seriously and will engage cooperatively to address the concerns.
Despite the FDA’s letter, Mayne Pharma clarified that it does not consider the issue to be material enough to impact share price in the long term. However, investor sentiment on the day reflected some concern, with the company’s shares dropping over 12% before a trading halt was announced just after midday on Wednesday.
The episode arrives during a period of transformation for Mayne Pharma. Earlier this year, US-based Cosette Pharmaceuticals placed a $672 million bid for the company, signaling confidence in the firm’s long-term product pipeline and market position. That acquisition interest has brought increased attention to Mayne’s operations and disclosures.
Mayne Pharma is part of the ASX300 index, a benchmark that includes 300 of the largest companies listed on the Australian Securities Exchange. Investors exploring this index often monitor performance across sectors including healthcare and pharmaceuticals.
In addition, some market participants viewing companies like Mayne Pharma within broader investment strategies may consider such stocks when examining ASX dividend stocks, although Mayne’s current focus appears centered more on regulatory management and operational adjustments rather than dividend distribution.
As Mayne Pharma prepares its formal response to the FDA, stakeholders will be watching closely for outcomes that may influence regulatory relationships and longer-term commercial prospects in the US market.
